Is Connect Biopharma Stock a Good Investment?
Connect Biopharma Investment Advice | CNTB |
- Examine Connect Biopharma's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Connect Biopharma's leadership team and their track record. Good management can help Connect Biopharma navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Connect Biopharma's business and its evolving consumer preferences.
- Compare Connect Biopharma's performance and market position to its competitors. Analyze how Connect Biopharma is positioned in terms of product offerings, innovation, and market share.
- Check if Connect Biopharma pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Connect Biopharma's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Connect Biopharma Holdings stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Connect Biopharma Holdings is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Solid | Details | |
Volatility | Very risky | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Moves slightly opposite to the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Not Available | Details | |
Financial Strenth (F Score) | Very Weak | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Possible Manipulator | Details |
Examine Connect Biopharma Stock
Researching Connect Biopharma's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 41.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 0.62. Some equities with similar Price to Book (P/B) outperform the market in the long run. Connect Biopharma recorded a loss per share of 0.31. The entity had not issued any dividends in recent years.
To determine if Connect Biopharma is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Connect Biopharma's research are outlined below:
| Connect Biopharma is way too risky over 90 days horizon | |
| Connect Biopharma may become a speculative penny stock | |
| Connect Biopharma appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 26.03 M. Net Loss for the year was (15.63 M) with profit before overhead, payroll, taxes, and interest of 26.03 M. | |
| Connect Biopharma Holdings currently holds about 1.28 B in cash with (23.61 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 23.26, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Connect Biopharma has a very weak financial position based on the latest SEC disclosures | |
| Roughly 41.0% of the company shares are held by company insiders |
Connect Biopharma uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Connect Biopharma Holdings. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Connect Biopharma's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 9th of April 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 9th of April 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Connect Biopharma's market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 103.34 M.Connect Biopharma's profitablity analysis
The company has Profit Margin (PM) of (0.66) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.82) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.82.Determining Connect Biopharma's profitability involves analyzing its financial statements and using various financial metrics to determine if Connect Biopharma is a good buy. For example, gross profit margin measures Connect Biopharma's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Connect Biopharma's profitability and make more informed investment decisions.
Please note, the presentation of Connect Biopharma's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Connect Biopharma's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Connect Biopharma's management manipulating its earnings.
Basic technical analysis of Connect Stock
As of the 19th of July, Connect Biopharma shows the Risk Adjusted Performance of 0.2238, downside deviation of 4.59, and Mean Deviation of 4.42. Connect Biopharma technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.Connect Biopharma's Outstanding Corporate Bonds
Connect Biopharma issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Connect Biopharma uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Connect bonds can be classified according to their maturity, which is the date when Connect Biopharma Holdings has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| CONNECTICUT LT PWR Corp BondUS207597DV42 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| CONNECTICUT LT PWR Corp BondUS207597EG65 | View | |
| CONNECTICUT LT PWR Corp BondUS207597EH49 | View | |
| CONNECTICUT LT PWR Corp BondUS207597EJ05 | View | |
| CONNECTICUT LT PWR Corp BondUS207597EL50 | View |
Understand Connect Biopharma's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Connect Biopharma's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.2238 | |||
| Market Risk Adjusted Performance | 6.26 | |||
| Mean Deviation | 4.42 | |||
| Semi Deviation | 3.5 | |||
| Downside Deviation | 4.59 | |||
| Coefficient Of Variation | 433.89 | |||
| Standard Deviation | 6.52 | |||
| Variance | 42.48 | |||
| Information Ratio | 0.2089 | |||
| Jensen Alpha | 1.46 | |||
| Total Risk Alpha | 0.5795 | |||
| Sortino Ratio | 0.2964 | |||
| Treynor Ratio | 6.25 | |||
| Maximum Drawdown | 39.41 | |||
| Value At Risk | (7.24) | |||
| Potential Upside | 11.76 | |||
| Downside Variance | 21.1 | |||
| Semi Variance | 12.25 | |||
| Expected Short fall | (5.73) | |||
| Skewness | 1.88 | |||
| Kurtosis | 7.06 |
| Risk Adjusted Performance | 0.2238 | |||
| Market Risk Adjusted Performance | 6.26 | |||
| Mean Deviation | 4.42 | |||
| Semi Deviation | 3.5 | |||
| Downside Deviation | 4.59 | |||
| Coefficient Of Variation | 433.89 | |||
| Standard Deviation | 6.52 | |||
| Variance | 42.48 | |||
| Information Ratio | 0.2089 | |||
| Jensen Alpha | 1.46 | |||
| Total Risk Alpha | 0.5795 | |||
| Sortino Ratio | 0.2964 | |||
| Treynor Ratio | 6.25 | |||
| Maximum Drawdown | 39.41 | |||
| Value At Risk | (7.24) | |||
| Potential Upside | 11.76 | |||
| Downside Variance | 21.1 | |||
| Semi Variance | 12.25 | |||
| Expected Short fall | (5.73) | |||
| Skewness | 1.88 | |||
| Kurtosis | 7.06 |
Consider Connect Biopharma's intraday indicators
Connect Biopharma intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Connect Biopharma stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 30518.19 | |||
| Daily Balance Of Power | (0.64) | |||
| Rate Of Daily Change | 0.92 | |||
| Day Median Price | 1.78 | |||
| Day Typical Price | 1.76 | |||
| Price Action Indicator | (0.13) | |||
| Period Momentum Indicator | (0.14) | |||
| Relative Strength Index | 73.33 |
Connect Stock media impact
There is far too much social signal, news, headlines, and media speculation about Connect Biopharma that are available to investors today. This information is accessible both publicly - through Connect Biopharma's media outlets and privately, via word of mouth or internal channels. However, regardless of the source, the sheer volume of Connect-related data is difficult to distill into actionable insights, especially for investors who are not well-versed in the rapidly evolving tools and techniques of investment management.
A primary focus of Connect Biopharma news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Connect Biopharma relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Connect Biopharma's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Connect Biopharma alpha.
Connect Biopharma Corporate Management
| Raul Collazo | VP Affairs | Profile | |
| Kimberly Manhard | Executive Officer | Profile | |
| Sean Ristine | Vice Resources | Profile | |
| Malinda Longphre | Head Operations | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Connect Biopharma Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Connect Biopharma. If investors know Connect will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Connect Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Connect Biopharma is measured differently than its book value, which is the value of Connect that is recorded on the company's balance sheet. Investors also form their own opinion of Connect Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Connect Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Connect Biopharma's market value can be influenced by many factors that don't directly affect Connect Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Connect Biopharma's value and its price, as these two are different measures arrived at by various means. Investors typically determine if Connect Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Connect Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.